Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

610
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
610
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

711
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
711
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

579
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
579
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.1K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental impact of brine from desalination plants on marine benthic diatom diversity.

Marine environmental research·2025
Same author

eDNA metabarcoding of marine invertebrate communities at RO desalination plant outfalls in Cyprus.

Marine pollution bulletin·2025
Same author

Integrated biological system for remediation and valorization of tannery wastewater: Focus on microbial communities responsible for methanogenesis and sulfidogenesis.

Bioresource technology·2024
Same author

GFR estimation is complicated by a high incidence of non-steady-state serum creatinine concentrations at the emergency department.

PloS one·2021
Same author

Listing criteria for heart transplantation in the Netherlands.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2021
Same author

Defining the variety of cell types in developing and adult human kidneys by single-cell RNA sequencing.

NPJ Regenerative medicine·2021
Same journal

Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.

Heart failure reviews·2026
Same journal

Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.

Heart failure reviews·2026
Same journal

Beyond the right ventricle: left heart involvement in pulmonary arterial hypertension.

Heart failure reviews·2026
Same journal

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same journal

Correction to: Left atrial shunting devices: why, what, how, and… when?

Heart failure reviews·2026
Same journal

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K

Left ventricular assist devices: a kidney's perspective.

T R Tromp1, N de Jonge, J A Joles

  • 1University Medical Center Utrecht, POB 85500, 3508 GA, Utrecht, The Netherlands, T.R.T.M.Tromp@students.uu.nl.

Heart Failure Reviews
|March 23, 2015
PubMed
Summary
This summary is machine-generated.

Left ventricular assist device (LVAD) implantation can improve chronic kidney disease (CKD) in heart failure patients. However, long-term kidney function changes after LVAD require further investigation.

More Related Videos

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

196
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Related Experiment Videos

Last Updated: Apr 16, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

196
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Area of Science:

  • Cardiology
  • Nephrology
  • Medical Devices

Background:

  • Heart failure often coexists with chronic kidney disease (CKD), frequently due to cardiorenal syndrome type II.
  • Left ventricular assist devices (LVADs) are a treatment for advanced heart failure.
  • The impact of LVADs on CKD progression and reversibility is not fully understood.

Purpose of the Study:

  • To investigate the effects of LVAD implantation on kidney function in patients with refractory heart failure and CKD.
  • To explore the predictability of CKD reversibility after LVAD therapy.
  • To understand the long-term renal outcomes in patients receiving LVAD support.

Main Methods:

  • Analysis of glomerular filtration rate (GFR) changes in patients before and after LVAD implantation.
  • Review of clinical data to identify predictors of CKD reversibility and outcomes.
  • Assessment of acute kidney injury (AKI) incidence and its relation to pre-existing CKD.

Main Results:

  • LVAD implantation often leads to initial improvement in GFR, alleviating CKD.
  • However, this GFR recovery can be transient, followed by a gradual late decline.
  • Pre-existing CKD and post-implantation AKI are mortality predictors, though AKI rates are decreasing.

Conclusions:

  • LVAD therapy can improve kidney function in heart failure patients, but long-term renal effects are complex.
  • The reversibility of CKD post-LVAD is difficult to predict, with a potential for late GFR decline.
  • Further research is needed to elucidate the long-term relationship between LVAD support and kidney function, especially in the growing destination therapy population.